The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 30, 2007
Filed:
Nov. 08, 2002
Vahe Bedian, East Lyme, CT (US);
Ronald P. Gladue, Stonington, CT (US);
Jose Corvalan, Foster City, CA (US);
Xiao-chi Jia, San Mateo, CA (US);
Xiao Feng, Union City, CA (US);
Vahe Bedian, East Lyme, CT (US);
Ronald P. Gladue, Stonington, CT (US);
Jose Corvalan, Foster City, CA (US);
Xiao-Chi Jia, San Mateo, CA (US);
Xiao Feng, Union City, CA (US);
Abgenix, Inc., Fremont, CA (US);
Pfizer Inc., New York, NY (US);
Abstract
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.